Dermatherix is a pioneering biotech company dedicated to advancing wound therapies through innovative research. ZZ Biotech is excited to see its drug 3K3A-APC advanced by the team at Dermatherix.

ZZ Biotech has been developing 3K3A-APC, a genetically engineered variant of human activated protein C (APC), a serine protease, that has been optimized for human therapeutic use. The company is pleased to announce it has agreed in principle to license its 3K3A-APC program in dermatology to Dermatherix, Pty Ltd.